Additional file 2: of Whole-exome sequencing identifies novel pathogenic mutations and putative phenotype-influencing variants in Polish limb-girdle muscular dystrophy patients

Lists of rare (< 1%) variants in genes related with “muscle phenotype” for individual patients. (XLSX 3003 kb

Additional file 1: Figure S1 of Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment

Weight loss in animals with colitis. O-1918 (5 mg/kg) and/or Abn-CBD (5 mg/kg) were given twice daily for 3 days to TNBS-treated mice. Weight of the animals was recorded daily. All animals lost weight throughout the duration of the experiment. Abn-CBD treatment did not decrease weight loss. No significant differences in weight loss were observed. (PPTX 3237 kb

Additional file 5: of Whole-exome sequencing identifies novel pathogenic mutations and putative phenotype-influencing variants in Polish limb-girdle muscular dystrophy patients

Selected genes with reported skeletal muscle expression which could contribute to LGMD. (DOCX 16 kb

Additional file 1: of Whole-exome sequencing identifies novel pathogenic mutations and putative phenotype-influencing variants in Polish limb-girdle muscular dystrophy patients

Clinical characteristics and WES results (including evidence of pathogenicity according to ACMG criteria) of 85 patients studied. (XLSX 24 kb

Additional file 3: of Whole-exome sequencing identifies novel pathogenic mutations and putative phenotype-influencing variants in Polish limb-girdle muscular dystrophy patients

List of variants in genes expressed in the human muscle and in genes whose mouse homologs are expressed in muscle, which are in the interactome of known LGMD- and MFM-associated genes. (XLSX 1451 kb

Additional file 4: of Whole-exome sequencing identifies novel pathogenic mutations and putative phenotype-influencing variants in Polish limb-girdle muscular dystrophy patients

List of copy number variants (CNVs) identified in the vicinity of LGMD-related genes. (XLS 2184 kb

Protective effect of AM841 (0.1 mg/kg, i.p.) injected once daily for 3 days on TNBS-induced colitis in mice.

<p>Figure shows data for (A) macroscopic score, (B) MPO activity, (C) ulcer score and (D) body weight. $$$p<0.001, as compared with control animals. **p<0.01, ***p<0.001, as compared with TNBS-treated mice. Data represent means ± SEM, n = 6–8.</p

Protective effect of AM841 (0.01, 0.1 and 1 mg/kg, i.p.) injected once daily for 7 days on DSS-induced colitis in mice.

<p>Figure shows data for (A) macroscopic score, (B) MPO activity, (C) body weight, (D) representative micrographs for hematoxylin and eosin staining of colon wall sections (i, control; ii, DSS; iii, DSS+AM841 0.01 mg/kg; iv, DSS+AM841 0.1 mg/kg; v, DSS+AM841 1 mg/kg; scale bar = 100 µm) and (E) microscopic score. $$$p<0.001, as compared with control animals. *p<0.05, ***p<0.001, as compared with DSS-treated mice. Data represent means ± SEM, n = 6–8.</p

Protective effect of CB 13 after central (0.1 µg/animal, i.c.v, OD), but not peripheral (0.1 mg/kg, i.p., OD) administration for 3 days on TNBS-induced colitis in mice.

<p>Figure shows data for (A) macroscopic score, (B) MPO activity and (C) ulcer score. **p<0.01, as compared with TNBS-treated mice. Data represent means ± SEM, n = 6–8.</p

Therapeutic effect of AM841 (0.1 mg/kg, i.p.) injected once or twice daily from day 4 on DSS-induced colitis in mice.

<p>Figure shows data for (A) macroscopic score, (B) MPO activity and (C) body weight. $$p<0.01,$$$p<0.001, as compared with control animals. *p<0.05, **p<0.01, as compared with DSS-treated mice. Data represent means ± SEM, n = 6–8.</p